We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
HUTCHMED China Limited | AQSE:HCM.GB | Aquis Stock Exchange | Ordinary Share | KYG4672N1198 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
4.00 | 1.33% | 304.00 | 290.00 | 310.00 | 305.79 | 299.87 | 300.00 | 62,752 | 08:24:14 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMHCM
RNS Number : 3158M
Hutchison China Meditech Limited
12 October 2016
Director's Share Dealing
London: Wednesday, October 12, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, has sold 15,000 ordinary shares of US$1.00 each in Chi-Med (the "Ordinary Shares") at a price of GBP17.90 per share on October 7, 2016.
Following the above transaction, the holding of Mr Howell is 138,600 Ordinary Shares, representing approximately 0.23% of the current issued share capital of Chi-Med.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person closely associated ---- ---------------------------------------------------------------------------------------------------------------- a) Name Mr Michael Howell ---- ------------------------------------------------------- ------------------------------------------------------- 2 Reason for the notification ---- ---------------------------------------------------------------------------------------------------------------- a) Position/status Independent Non-executive Director of Chi-Med ---- ------------------------------------------------------- ------------------------------------------------------- b) Initial notification/Amendment Initial notification ---- ------------------------------------------------------- ------------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ---- ---------------------------------------------------------------------------------------------------------------- a) Name Hutchison China MediTech Limited ---- ------------------------------------------------------- ------------------------------------------------------- b) LEI N/A ---- ------------------------------------------------------- ------------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---- ---------------------------------------------------------------------------------------------------------------- a) Description of the financial instrument, type of Ordinary Shares of US$1.00 each instrument DI ISIN: KYG4672N1016 Identification code ADS ISIN: US44842L1035 ---- ------------------------------------------------------- ------------------------------------------------------- b) Nature of the transaction Sale of 15,000 Ordinary Shares on October 7, 2016 at a price of GBP17.90 ---- ------------------------------------------------------- ------------------------------------------------------- c) Price(s) and volume(s) Price(s) Volume(s) ---------- ---------- GBP17.90 15,000 ---------- ---------- ---- ------------------------------------------------------- ------------------------------------------------------- d) Aggregated information N/A - Aggregated volume - Price ---- ------------------------------------------------------- ------------------------------------------------------- e) Date of the transaction 2016-10-07 ---- ------------------------------------------------------- ------------------------------------------------------- f) Place of the transaction London Stock Exchange (XLON) ---- ------------------------------------------------------- -------------------------------------------------------
NOTES TO EDITORS
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
Contacts
Investor Enquiries Christian Hogg, CEO +852 2121 8200 International Media Enquiries Anthony Carlisle, +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk Citigate Dewe Rogerson U.S. Based Media Enquiries Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com Investor Relations Matt Beck, The Trout Group +1-646-378-2933 (Mobile) mbeck@troutgroup.com David Dible, +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk Citigate Dewe Rogerson Panmure Gordon (UK) Limited Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLIFSEIVLFLIR
(END) Dow Jones Newswires
October 12, 2016 02:00 ET (06:00 GMT)
1 Year HUTCHMED China Chart |
1 Month HUTCHMED China Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions